查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1590857

移植物抗宿主疾病治疗市场：按疾病类型、产品类型和最终用户划分 - 2025-2030 年全球预测

Graft Versus Host Disease Treatment Market by Disease Type (Acute Graft Versus Host Disease, Chronic Graft Versus Host Disease), Product (Corticosteroids, Monoclonal Antibodies, Tyrosine Kinase Inhibitors), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

移植物抗宿主疾病治疗市场2023年估值为18.7亿美元，预计2024年将达20.6亿美元，复合年增长率为10.45%，2030年将达37.6亿美元，预计将达到1000万美元。

移植物抗宿主疾病（GVHD）治疗通常涉及旨在减弱移植后供体来源的免疫细胞攻击受体身体组织时的免疫反应的药物和治疗方法。这些治疗方法在确保移植成功和患者存活（尤其是骨髓和干细胞移植患者）方面的关键作用凸显了对这些治疗方法的需求。应用范围包括皮质类固醇、TNF 抑制剂等药物和针对急性和慢性 GVHD 症状的新型生物製药。最终用途主要是在医院和专科移植中心，由能够管理复杂治疗方法的熟练医疗保健专业人员提供支援。这个市场主要是由移植手术数量的增加、先进的诊断以及新型免疫抑制疗法的研究和开发的增加所推动的。基因组技术和生物标记发现的进步正在吸引人们对个人化医疗和精准免疫疗法的关注，从而实现量身定制的治疗。生物技术公司之间的策略联盟、增加的医疗保健资金和监管支援将促进产品创新和市场进入。

主要市场统计
基准年[2023] 18.7亿美元
预测年份 [2024] 20.6亿美元
预测年份 [2030] 37.6亿美元
复合年增长率（%） 10.45%

挑战包括先进治疗方法的高成本、监管障碍以及与现有免疫抑制药物相关的副作用，这些副作用可能导致继发性感染和恶性。此外，疾病机制的复杂性对开发普遍有效的治疗方法构成了主要障碍。 GVHD 发病的可预测性和症状的有限变异性需要更具适应性的治疗方法，并且很难将临床结果与患者需求相匹配。

创新研究领域包括精确调节免疫反应的 CRISPR 等基因编辑技术、基于微生物的治疗方法的开发以及使用 CAR-T 和 Tregs 增强细胞疗法。市场本质上是动态的，倾向于采用个人化、技术主导的方法来有效地解决未满足的需求。因此，企业可以透过专注于策略伙伴关係关係、以患者为中心的临床试验和技术整合来抓住潜在的业务成长机会，以推动有效的产品开发，同时克服挑战。

市场动态：揭示快速发展的移植物抗宿主疾病治疗市场的关键市场见解

供需的动态交互作用正在改变移植物抗宿主疾病治疗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 由于航空货运收入和吨位增加，大件和重型货物增加
    • 同种异体移植数量的增加
    • 接受异体造血干细胞移植的患者数量不断增加
  • 市场限制因素
    • 数位化造成的破坏以及加快全球货物运输的要求
    • 与其他交通工具的竞争
    • 治疗方法的临床进展
  • 市场机会
    • 新兴市场货运服务的成长
    • 新飞机技术数位化的技术发展
  • 市场挑战
    • 贸易紧张局势和行业监管收紧

波特的五力战略工具驾驭移植物抗宿主疾病治疗市场

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解移植物抗宿主疾病治疗市场的外部影响

外部宏观环境因素在塑造移植物抗宿主疾病治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解移植物抗宿主疾病治疗市场的竞争格局

移植物抗宿主疾病治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的见解，以应对日益激烈的竞争。

FPNV定位矩阵移植物抗宿主疾病治疗市场供应商绩效评估

FPNV 定位矩阵是评估移植物抗宿主疾病治疗市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了移植物抗宿主疾病治疗市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，移植物抗宿主疾病治疗市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 航空货运收入和负载容量的增加增加了对大件和重型货物的需求
      • 同种异体移植的增加
      • 接受异体造血干细胞移植的患者数量不断增加
    • 抑制因素
      • 数位化和加速全球货物流动的需求造成的破坏
      • 与其他交通途径的竞争
      • 治疗程序的临床进展
    • 机会
      • 新兴市场货运服务的成长
      • 新型飞机技术与数位化技术开发
    • 任务
      • 贸易紧张局势及产业监管加强
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章移植物抗宿主疾病治疗市场：依疾病类型

  • 急性移植物抗宿主疾病
  • 慢性移植物抗宿主疾病

第七章移植物抗宿主疾病治疗市场：副产品

  • 皮质类固醇
  • 单株抗体
  • 蛋白酪氨酸激酶抑制剂

第八章移植物抗宿主疾病治疗市场：依最终用户分类

  • 医院药房
  • 网路药房
  • 零售药房

第九章 美洲移植物抗宿主疾病治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太移植物抗宿主疾病治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲的移植物抗宿主疾病治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Bristol-Myers Squibb Company
  • ElsaLys Biotech SA
  • Johnson & Johnson Services, Inc.
  • Mallinckrodt LLC
  • Merck KGaA
  • Mesoblast Limited
  • Neovii Pharmaceuticals AG
  • Novartis AG
  • Ocugen, Inc.
  • Pfizer Inc
  • Pluristem Therapeutics Inc.
  • Sanofi SA
  • Soligenix, Inc.
Product Code: MRR-43676CF42284

The Graft Versus Host Disease Treatment Market was valued at USD 1.87 billion in 2023, expected to reach USD 2.06 billion in 2024, and is projected to grow at a CAGR of 10.45%, to USD 3.76 billion by 2030.

Graft Versus Host Disease (GVHD) treatment typically encompasses pharmaceuticals and therapies aimed at attenuating the immune response when donor-derived immune cells attack the recipient's body tissue post-transplant. The necessity of these treatments is underscored by their critical role in ensuring transplant success and patient survival, especially in bone marrow and stem cell transplant patients. The application spans a range of pharmaceuticals like corticosteroids, TNF inhibitors, and novel biologics, targeting both acute and chronic GVHD manifestations. End-use scope prominently features hospitals and specialized transplant centers, backed by skilled healthcare professionals capable of handling complex treatment regimens. The market is primarily driven by rising transplantation procedures, advanced diagnostics, and increased R&D for novel immunosuppressive therapies. Emerging opportunities focus on personalized medicine and precision immunotherapies, aided by advances in genomic technologies and biomarker discovery, allowing tailored treatment pathways. Strategic collaboration between biotech firms, increased healthcare funding, and regulatory support enhances product innovation and market reach.

KEY MARKET STATISTICS
Base Year [2023] USD 1.87 billion
Estimated Year [2024] USD 2.06 billion
Forecast Year [2030] USD 3.76 billion
CAGR (%) 10.45%

Challenges include the high cost of advanced therapies, regulatory hurdles, and side effects associated with existing immunosuppressants, which can contribute to secondary infections and malignancies. Additionally, the complexity of disease mechanisms poses significant barriers in developing universally efficacious treatments. Limited predictability of GVHD onset and variability of symptoms necessitate more adaptive therapeutic approaches, presenting hurdles in aligning clinical outcomes with patient needs.

Innovative research areas include gene editing technologies like CRISPR to modulate immune responses precisely, development of microbiome-based therapies, and enhanced cellular therapies using CAR-T and Tregs. The market, inherently dynamic, gravitates towards adopting personalized and technology-driven approaches to address unmet needs efficiently. Therefore, companies should focus on strategic partnerships, patient-centric trials, and technology integration to drive effective product development while navigating challenges, offering potential business growth opportunities.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Graft Versus Host Disease Treatment Market

The Graft Versus Host Disease Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increases in air cargo revenue and tonnage to boost bulky and heavy cargo
    • Growing number of allogeneic transplantations
    • Rising number of patients undergoing allogeneic haematopoietic stem cell transplants
  • Market Restraints
    • Disruption through digitization and demand to speed-up the movement of goods across the globe
    • Competition from other transport modes
    • Clinical advancements in the treatment procedure
  • Market Opportunities
    • Growth of cargo services in emerging markets
    • Technological developments in new aircraft technologies and the digitization
  • Market Challenges
    • Trade tensions and increasing industry regulation

Porter's Five Forces: A Strategic Tool for Navigating the Graft Versus Host Disease Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Graft Versus Host Disease Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Graft Versus Host Disease Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Graft Versus Host Disease Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Graft Versus Host Disease Treatment Market

A detailed market share analysis in the Graft Versus Host Disease Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Graft Versus Host Disease Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Graft Versus Host Disease Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Graft Versus Host Disease Treatment Market

A strategic analysis of the Graft Versus Host Disease Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Graft Versus Host Disease Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Astellas Pharma Inc., Bristol-Myers Squibb Company, ElsaLys Biotech SA, Johnson & Johnson Services, Inc., Mallinckrodt LLC, Merck KGaA, Mesoblast Limited, Neovii Pharmaceuticals AG, Novartis AG, Ocugen, Inc., Pfizer Inc, Pluristem Therapeutics Inc., Sanofi S.A., and Soligenix, Inc..

Market Segmentation & Coverage

This research report categorizes the Graft Versus Host Disease Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease Type, market is studied across Acute Graft Versus Host Disease and Chronic Graft Versus Host Disease.
  • Based on Product, market is studied across Corticosteroids, Monoclonal Antibodies, and Tyrosine Kinase Inhibitors.
  • Based on End-User, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increases in air cargo revenue and tonnage to boost bulky and heavy cargo
      • 5.1.1.2. Growing number of allogeneic transplantations
      • 5.1.1.3. Rising number of patients undergoing allogeneic haematopoietic stem cell transplants
    • 5.1.2. Restraints
      • 5.1.2.1. Disruption through digitization and demand to speed-up the movement of goods across the globe
      • 5.1.2.2. Competition from other transport modes
      • 5.1.2.3. Clinical advancements in the treatment procedure
    • 5.1.3. Opportunities
      • 5.1.3.1. Growth of cargo services in emerging markets
      • 5.1.3.2. Technological developments in new aircraft technologies and the digitization
    • 5.1.4. Challenges
      • 5.1.4.1. Trade tensions and increasing industry regulation
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Graft Versus Host Disease Treatment Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Acute Graft Versus Host Disease
  • 6.3. Chronic Graft Versus Host Disease

7. Graft Versus Host Disease Treatment Market, by Product

  • 7.1. Introduction
  • 7.2. Corticosteroids
  • 7.3. Monoclonal Antibodies
  • 7.4. Tyrosine Kinase Inhibitors

8. Graft Versus Host Disease Treatment Market, by End-User

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Americas Graft Versus Host Disease Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Graft Versus Host Disease Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Graft Versus Host Disease Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Astellas Pharma Inc.
  • 3. Bristol-Myers Squibb Company
  • 4. ElsaLys Biotech SA
  • 5. Johnson & Johnson Services, Inc.
  • 6. Mallinckrodt LLC
  • 7. Merck KGaA
  • 8. Mesoblast Limited
  • 9. Neovii Pharmaceuticals AG
  • 10. Novartis AG
  • 11. Ocugen, Inc.
  • 12. Pfizer Inc
  • 13. Pluristem Therapeutics Inc.
  • 14. Sanofi S.A.
  • 15. Soligenix, Inc.

LIST OF FIGURES

  • FIGURE 1. GRAFT VERSUS HOST DISEASE TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. GRAFT VERSUS HOST DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. GRAFT VERSUS HOST DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GRAFT VERSUS HOST DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GRAFT VERSUS HOST DISEASE TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ACUTE GRAFT VERSUS HOST DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY CHRONIC GRAFT VERSUS HOST DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. GRAFT VERSUS HOST DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 146. GRAFT VERSUS HOST DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023